Status and phase
Conditions
Treatments
About
The prognosis of NSCLC patients with asymptomatic brain metastasis, who are not treated with SRS or WBRT has not been fully investigated yet. This randomized phase III trial is conducted to determine the exact role of SRS in NSCLC patients with asymptomatic oligo brain metastases whether early treatment with SRS would improve survival even in patients with asymptomatic brain metastasis.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Histologically confirmed non-small cell lung cancer with synchronous brain metastases (diagnosis of brain lesion before or within 2 months from diagnosis of the primary site tumor)
One to 4 intraparenchymal brain metastases by contrast-enhanced MRI, meeting the following criteria:
Well circumscribed tumor(s) with brain edema Grade 0-1
Maximum diameter ≤ 3.0 cm
No prior complete resection of all known brain metastases or RT ④ No leptomeningeal metastases by MRI or cerebrospinal fluid evaluation
Exclusion Criteria:
severe co-morbid illness and/or active infections ② pregnant or lactating women
Primary purpose
Allocation
Interventional model
Masking
176 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal